{"product_id":"harrowinc-business-model-canvas","title":"Harrow Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow Business Model Canvas: Strategic Blueprint for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Harrow’s business model—this comprehensive Business Model Canvas dissects value propositions, customer segments, revenue streams, and cost drivers to reveal how Harrow competes and scales; ideal for investors, consultants, and founders seeking actionable, ready-to-use insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHarrow contracts specialized CDMOs (contract development and manufacturing organizations) to produce branded drugs like VEVYE and IHEEZO under strict FDA cGMPs, keeping capital expenditure low and supporting \u0026gt;95% on‑time supply in 2025. By outsourcing manufacturing, Harrow stays asset‑light in its branded arm, freeing ~60% of R\u0026amp;D\/commercial spend for marketing and M\u0026amp;A instead of heavy plant investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with Group Purchasing Organizations (GPOs) give Harrow broad US market access and better pricing: GPO members account for roughly 90% of US hospitals and 60% of surgical centers, so preferred-formulary placement can boost annual unit volumes by 20–40% and cut COGS by 5–12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow partners with top universities and eye research centers—funding 12 clinical trials since 2021 and co-authoring 8 peer‑reviewed papers in 2024—to validate formulations and expand indications through randomized studies; this collaboration cut time‑to‑market by an estimated 18% on recent products. By aligning with leading academic teams, Harrow boosts clinical credibility and gains early access to emerging therapies and biomarkers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow partners with major wholesalers McKesson and AmerisourceBergen to handle national warehousing, inventory control, and next‑day delivery, enabling distribution to ~20,000 pharmacies and clinics and supporting peak weekly volumes above 50,000 ophthalmic units as of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMcKesson \u0026amp; AmerisourceBergen: national logistics backbone\u003c\/li\u003e\n\u003cli\u003eWarehousing + inventory tech: reduces stockouts to \u0026lt;2% nationally\u003c\/li\u003e\n\u003cli\u003eNext‑day delivery: supports ~50k units\/week peak\u003c\/li\u003e\n\u003cli\u003eEnsures access to branded and compounded ophthalmics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHarrow partners with institutional investors and lenders to fund acquisitions, accessing roughly $200–300m in committed capital as of Q4 2025 to buy undervalued or non-core ophthalmic assets from Big Pharma.\u003c\/p\u003e\n\u003cp\u003eActive credit and covenant management keeps liquidity at target \u0026gt;$50m and maintains net leverage near 2.0x, enabling steady portfolio expansion and timely debt servicing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommitted capital: $200–300m\u003c\/li\u003e\n\u003cli\u003eLiquidity target: \u0026gt;$50m\u003c\/li\u003e\n\u003cli\u003eNet leverage: ~2.0x\u003c\/li\u003e\n\u003cli\u003eFocus: non-core ophthalmic assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow: Asset‑light network hits \u0026gt;95% on‑time, ~20k sites, $200–300M acquisition firepower\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow leverages CDMOs, GPOs, academic centers, and wholesalers to stay asset‑light, achieve \u0026gt;95% on‑time supply, reach ~20,000 dispensing sites, and access $200–300m acquisition capital, keeping liquidity \u0026gt;$50m and net leverage ~2.0x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eOn‑time supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eHospital coverage\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eDispense sites\u003c\/td\u003e\n\u003ctd\u003e~20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003eCommitted capital\u003c\/td\u003e\n\u003ctd\u003e$200–300m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$50m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage\u003c\/td\u003e\n\u003ctd\u003eNet\u003c\/td\u003e\n\u003ctd\u003e~2.0x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Harrow Business Model Canvas aligning the company’s strategy with nine BMC blocks, delivering clear value propositions, customer segments, channels, and revenue logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Harrow’s strategy into a digestible one-page snapshot, saving hours of formatting while remaining fully editable for team collaboration and quick comparison across models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Asset Acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA primary activity for Harrow targets identifying and acquiring ophthalmic drugs that fill gaps or unmet needs; deals often screen for clinical efficacy, market size, and portfolio synergy—Harrow completed 3 bolt-on ophthalmic acquisitions in 2024, adding assets with combined peak sales estimates of $220m. After close, Harrow integrates assets into its commercial engine to drive uptake via focused marketing and a 45-person specialty sales force.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Compounding Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough ImprimisRx, Harrow Pharmaceuticals compounds customized sterile ophthalmic meds unavailable commercially, operating ISO-class cleanrooms and USP \u0026lt;797\u0026gt; sterile compounding protocols to minimize contamination risk; in 2024 ImprimisRx generated about $58M of Harrow’s $210M revenue, reflecting demand for personalized surgical formulations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Sales and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow uses a specialized sales force focused on ophthalmologists and optometrists to drive adoption of TRIESENCE and VEVYE via direct clinical detailing and in‑clinic training; in 2024 these reps supported ~3,200 accounts and helped grow TRIESENCE unit sales by ~12% YoY. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow allocates roughly 12% of 2024 revenue (about $28M of $235M) to regulatory compliance and quality assurance, funding continuous GMP monitoring, adverse-event reporting, and FDA\/state board submissions to maintain licenses and approvals.\u003c\/p\u003e\n\u003cp\u003eRobust compliance cuts legal risk—recall rates under 0.3% in 2024—and preserves reputation while supporting timely drug approval renewals and reducing potential fines (average industry penalties \u0026gt;$2M per enforcement action).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of revenue ~ $28M (2024)\u003c\/li\u003e\n\u003cli\u003eContinuous GMP monitoring\u003c\/li\u003e\n\u003cli\u003eAdverse-event reporting \u0026amp; documentation\u003c\/li\u003e\n\u003cli\u003eRecall rate \u0026lt;0.3% (2024)\u003c\/li\u003e\n\u003cli\u003eReduces legal fines (avg \u0026gt;$2M)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Optimization and R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarrow reviews its eye-care portfolio quarterly, reallocating about 20% of marketing spend toward top-performing therapeutic areas and targeting a 15% CAGR in specialty ophthalmics by 2025 through R and D investment.\u003c\/p\u003e\n\u003cp\u003eR and D focuses on improving formulations and delivery (e.g., sustained-release drops), allowing phase-out of low-margin SKUs and concentration on products with \u0026gt;25% gross margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly portfolio reviews\u003c\/li\u003e\n\u003cli\u003e20% marketing reallocation\u003c\/li\u003e\n\u003cli\u003e15% target CAGR to 2025\u003c\/li\u003e\n\u003cli\u003eR and D on sustained-release delivery\u003c\/li\u003e\n\u003cli\u003eFocus on \u0026gt;25% gross-margin products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarrow bolsters eye portfolio with 3 bolt‑ons, $235M rev, targeting 15% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow acquires ophthalmic assets (3 bolt-ons in 2024; combined peak sales $220M), integrates via a 45-person specialty sales force (3,200 accounts; TRIESENCE units +12% YoY), and runs ImprimisRx sterile compounding (2024 revenue ~$58M of $235M). Compliance\/GMP costs ~12% rev (~$28M); recall rate \u0026lt;0.3%; portfolio reviews quarterly, 20% marketing reallocation, target 15% CAGR to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBolt-on deals\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales est.\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprimisRx rev\u003c\/td\u003e\n\u003ctd\u003e$58M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal rev\u003c\/td\u003e\n\u003ctd\u003e$235M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e12% (~$28M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccounts\u003c\/td\u003e\n\u003ctd\u003e3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget CAGR\u003c\/td\u003e\n\u003ctd\u003e15% to 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Harrow Business Model Canvas previewed here is the exact, live document you’ll receive after purchase—not a mockup or sample; it’s a direct snapshot of the final file.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll gain access to this same professional, fully editable Business Model Canvas formatted for immediate use—no changes, no surprises.\u003c\/p\u003e\n\u003cp\u003eThis preview reflects the complete structure and content of the deliverable, ready for download, presentation, and implementation in the same layout you see now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749588742521,"sku":"harrowinc-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harrowinc-business-model-canvas.png?v=1772215599","url":"https:\/\/matrixbcg.com\/products\/harrowinc-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}